Partners Capital Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Partners Capital Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-340,086	Closed	-$53.1M	–	158
2020 Q4	$53.1M	Buy	340,086 +174,620	+106%	+$22.4M	1.52%	21
2020 Q3	$18.9M	Buy	165,466 +25,476	+18%	+$2.75M	1.17%	29
2020 Q2	$15.7M	Buy	139,990 +36,303	+35%	+$3.85M	0.77%	36
2020 Q1	$9.31M	Buy	103,687 +30,251	+41%	+$2.97M	0.64%	39
2019 Q4	$7.94M	Buy	73,436 +1,828	+3%	+$196K	0.6%	46
2019 Q3	$7.01M	Buy	71,608 +19,728	+38%	+$2.22M	0.61%	48
2019 Q2	$6.79M	Buy	51,880 +4,451	+9%	+$574K	0.68%	46
2019 Q1	$6.41M	Buy	47,429 +5,402	+13%	+$672K	0.63%	41
2018 Q4	$4.09M	Buy	42,027 +13,790	+49%	+$1.63M	0.49%	52
2018 Q3	$3.92M	Buy	28,237 +3,644	+15%	+$457K	0.42%	47
2018 Q2	$3.05M	Buy	24,593 +5,099	+26%	+$596K	0.39%	49
2018 Q1	$2.17M	Buy	19,494 +10,661	+121%	+$1.27M	0.29%	52
2017 Q4	$1.06M	Buy	8,833 +4,400	+99%	+$536K	0.17%	51
2017 Q3	$622K	Buy	+4,433	New	+$602K	0.1%	45

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Partners Capital Investment Group's ALXN Position: Q1 2021 in Review

Partners Capital Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 340,086 shares — an estimated $53.1M sold.

Partners Capital Investment Group first reported a position in ALXN in Q3 2017 and held it in 14 quarters. The position peaked at $53.1M in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Partners Capital Investment Group reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Partners Capital Investment Group sold 340,086 Alexion Pharmaceuticals shares in Q1 2021, an estimated $53.1M.
Partners Capital Investment Group first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 14 quarters.
Partners Capital Investment Group's Alexion Pharmaceuticals position peaked at $53.1M in Q4 2020.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Partners Capital Investment Group's 13F filing for Q1 2021, filed 17 May 2021.